Lorlatinib vs Crizotinib in Patients With Advanced ALK-Positive NSCLC: 5-Year Outcomes from the Phase III CROWN Study

Opinion
Video

Focusing on the CROWN study, Faith Abodunrin, MD, discusses the role of lorlatinib in the treatment of patients with non–small cell lung cancer.

CN_FO_NSCLC_Seg03_CROWN_1
Video Player is loading.
Current Time 0:00
Duration 8:23
Loaded: 1.96%
Stream Type LIVE
Remaining Time 8:23
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected
    Related Content